Alnylam Pharmace. buy Evercore ISI
Start price
25.06.24
/
50%
€221.10
Target price
25.06.25
€242.92
Performance (%)
25.69%
End price
26.06.25
€277.90
Summary
This prediction ended on 26.06.25 with a price of €277.90. The BUY prediction by Evercore_ISI finished with a performance of 25.69%. Evercore_ISI has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 2.484% | 2.484% | -49.814% |
| iShares Core DAX® | -1.283% | 4.209% | 7.084% |
| iShares Nasdaq 100 | -3.338% | -1.744% | 26.177% |
| iShares Nikkei 225® | -4.286% | -1.621% | 44.320% |
| iShares S&P 500 | -2.311% | -0.096% | 20.823% |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Evercore ISI from $210.00 to $260.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Evercore_ISI gewählte maximale Laufzeit wurde überschritten
Current prediction by Evercore_ISI for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€399.10
11.09.25
11.09.25
€440.26
11.09.26
11.09.26
-49.34%
21.08.26
21.08.26
